What Does ICD-10 Code J84.89 Mean?
ICD-10-CM code J84.89 — Other specified interstitial pulmonary diseases — is a billable diagnosis code used when a clinician has identified a specific form of interstitial lung disease (ILD) that does not map to a more granular code elsewhere in the J84 category. It sits under Chapter 10 (Diseases of the Respiratory System), within the subsection J80–J84 covering diseases principally affecting the pulmonary interstitium.
Key attributes of J84.89 at a glance:
- Valid and billable for fiscal year 2026 (October 1, 2025 through September 30, 2026)
- Not a “not otherwise specified” catch-all — the provider must identify a specific ILD type that falls outside more granular J84 sub-codes
- Applicable in both inpatient and outpatient settings (default Y for both)
- May require additional codes to capture the underlying cause (drug, toxin, or connective tissue disease)
- First introduced as a new ICD-10-CM code in FY 2016 with the initial ICD-10 implementation
What Conditions and Diagnoses Does J84.89 Cover?
J84.89 applies when the documented interstitial lung disease has a defined clinical character but does not align with a more specific code. Conditions that map to this code include:
- Endogenous lipoid pneumonia (cholesterol pneumonitis arising from within the body, not from aspiration)
- Interstitial pneumonitis (documented without further specification of idiopathic or connective tissue–associated type)
- Non-specific interstitial pneumonitis NOS (when the provider describes NSIP but does not confirm idiopathic origin)
- Organizing pneumonia NOS (when the provider documents OP but cannot confirm cryptogenic origin)
- Interstitial lung disease associated with connective tissue diseases (e.g., rheumatoid arthritis–associated ILD, lupus-associated ILD, Sjögren syndrome–associated ILD)
- Interstitial lung disease with a documented but non-idiopathic etiology that does not have a dedicated code elsewhere
What Does J84.89 Specifically Exclude?
The following conditions carry their own codes and must never be reported using J84.89 (Excludes1 — cannot be coded together):
- Cryptogenic organizing pneumonia → J84.116
- Idiopathic non-specific interstitial pneumonitis → J84.113
- Lipoid pneumonia, exogenous or unspecified (aspiration-related) → J69.1
- Lymphoid interstitial pneumonia → J84.2
Additional conditions excluded from the parent J84 category (Excludes2 — may coexist):
- Drug-induced interstitial lung disorders (J70.2–J70.4)
- Interstitial emphysema (J98.2)
- Lung diseases due to external agents (J60–J70)
When Is J84.89 the Right Code to Use?
J84.89 is appropriate only after a methodical process of code exclusion. In practice, this code functions as the “named but uncategorized” slot within the J84 family — not a default fallback. Use this sequential decision framework:
- Confirm the provider has specified the type of ILD — vague language like “lung disease” or “respiratory issues” does not support any J84 code.
- Check whether the condition is idiopathic — if the provider documents idiopathic NSIP, use J84.113; if they document idiopathic pulmonary fibrosis confirmed by HRCT and multidisciplinary discussion (MDD), use J84.112.
- Check whether fibrosis is documented — if progressive fibrosis is the primary finding and a systemic disease is present, consider J84.17x codes.
- Evaluate for organizing pneumonia — if cryptogenic (no known cause), use J84.116; if organizing pneumonia is documented without the cryptogenic qualifier, J84.89 may apply.
- Evaluate for a connective tissue disease link — if the provider links the ILD to rheumatoid arthritis, SLE, or another CTD, J84.89 is the appropriate code (with the underlying CTD coded first per sequencing rules).
- Rule out all Excludes1 codes listed above before finalizing J84.89.
- Apply any required additional codes — for drug-induced pneumonopathy, assign a T36–T50 code with fifth or sixth character “5” to identify the causative drug.
How Does J84.89 Differ From J84.9 and J84.113?
Understanding where J84.89 sits among its neighbors is one of the most common coder pain points in this subcategory.
| Code | Description | Key Distinction | When to Use |
|---|---|---|---|
| J84.89 | Other specified interstitial pulmonary diseases | Named ILD type that doesn’t fit a more specific code | Connective tissue–associated ILD, non-idiopathic NSIP, organizing pneumonia NOS, endogenous lipoid pneumonia |
| J84.9 | Interstitial pulmonary disease, unspecified | Completely unspecified — no type identified | Only when documentation provides no further clinical detail after query |
| J84.113 | Idiopathic non-specific interstitial pneumonitis | Specifically idiopathic NSIP — no known cause | NSIP with no identifiable underlying disease or drug trigger |
| J84.116 | Cryptogenic organizing pneumonia | Organizing pneumonia with no identifiable cause | OP confirmed as cryptogenic by multidisciplinary evaluation |
| J84.112 | Idiopathic pulmonary fibrosis | UIP pattern confirmed by HRCT ± MDD, no CTD | Classic IPF with documented HRCT and MDD confirmation |
In practice, coders frequently misassign J84.9 when J84.89 is the correct code because the documentation appears vague but actually contains enough clinical specificity — such as a confirmed connective tissue disease association — to support the more specific choice.
What Documentation Is Required to Support J84.89?
Strong documentation is the foundation of any defensible J84.89 claim. The interstitial lung disease category is an active area of clinical and billing complexity, and payers increasingly scrutinize ILD claims for medical necessity.
What Must the Provider Document in the Clinical Notes?
The physician or treating pulmonologist must include:
- Explicit diagnosis statement identifying the specific type or cause of interstitial lung disease (e.g., “ILD associated with rheumatoid arthritis,” “organizing pneumonia,” or “endogenous lipoid pneumonia”)
- Exclusion of idiopathic and cryptogenic causes when applicable — particularly for NSIP and organizing pneumonia, which have their own more specific codes
- Underlying condition if the ILD is secondary to a connective tissue disease, autoimmune disorder, or drug exposure
- Clinical course and functional impact — symptom progression, oxygen requirements, exercise tolerance, pulmonary function trends
- Multidisciplinary discussion notes when the diagnosis was reached through MDD (common in academic ILD centers)
- Response to treatment or management plan for medical necessity documentation on follow-up claims
Which Diagnostic Tests Support This Code?
Supporting documentation commonly includes:
- High-resolution CT (HRCT) of the chest — the cornerstone imaging modality; report must describe pattern (NSIP, UIP, organizing pneumonia, etc.)
- Pulmonary function testing (PFTs) — spirometry, DLCO, and lung volumes to characterize restriction and impairment
- Bronchoscopy with bronchoalveolar lavage (BAL) — cellular analysis to support or exclude specific diagnoses
- Surgical lung biopsy pathology — histopathologic pattern used to confirm diagnosis when imaging is inconclusive
- Serologic testing — ANA, RF, anti-CCP, anti-Scl-70, anti-Jo-1 and other CTD-specific autoantibodies when connective tissue disease is suspected
- Echocardiogram — to document or exclude pulmonary hypertension as a complication (supports additional code I27.2x)
What Is the Documentation Standard for Inpatient vs. Outpatient Settings?
| Setting | Documentation Standard |
|---|---|
| Outpatient | Confirmed diagnosis only — code only conditions confirmed at the time of the visit; do not code “probable” or “suspected” ILD |
| Inpatient | May code probable, suspected, or working diagnoses when confirmed to the coder’s best knowledge at the time of discharge (per ICD-10-CM Official Coding Guidelines Section II) |
| Both | Underlying CTD or causative drug must be documented and coded in addition to J84.89 when applicable |
How Does J84.89 Affect Medical Billing and Claims?
J84.89 falls within MS-DRG v43.0 groupings for respiratory diagnoses, which determines inpatient reimbursement under Medicare. For outpatient claims, medical necessity must be clearly established in the clinical notes — payers do not reimburse ILD-related services on the basis of a code alone.
Key billing considerations:
- Medical necessity documentation must connect the ILD diagnosis to the services rendered — an office visit, pulmonary function test, or HRCT must be clinically justified
- Sequencing matters for CTD-associated ILD — the underlying connective tissue disease (e.g., M05.xx for seropositive RA) should be listed as the principal or first-listed diagnosis in most outpatient scenarios when it is the primary reason for the encounter
- Drug-induced cases require dual coding — J84.89 alone is insufficient; the causative drug must be identified via T36–T50 codes
- Electronic submission — omit the decimal point; submit as J8489, not J84.89, on electronic claims to avoid formatting-based rejections
What CPT Codes Are Commonly Billed With J84.89?
| CPT Code | Description | Typical Pairing Context |
|---|---|---|
| 94010 | Spirometry | Baseline and follow-up PFTs in ILD monitoring |
| 94726 | Plethysmography for lung volumes | Characterizing restriction in ILD |
| 94729 | Diffusing capacity (DLCO) | Monitoring gas transfer impairment |
| 71250 | CT thorax without contrast | HRCT chest for ILD pattern evaluation |
| 31623 | Bronchoscopy with BAL | Diagnostic workup for undifferentiated ILD |
| 99213–99215 | Office/outpatient E/M | Pulmonologist follow-up visits |
| 94060 | Bronchodilator spirometry | Assessing reversibility component |
Are There Prior Authorization or Coverage Restrictions?
- Nintedanib (Ofev) and pirfenidone (Esbriet) — antifibrotic agents used in ILD-related indications often require prior authorization; ICD-10 documentation must confirm the specific diagnosis to support PA requests
- Surgical lung biopsy (CPT 32669) — payers may require prior auth, with medical necessity tied to HRCT findings and inability to reach diagnosis non-invasively
- Home oxygen (E0424–E1390) — requires documented room-air oxygen saturation ≤88% or PaO2 ≤55 mmHg per CMS LCD criteria; J84.89 alone does not guarantee oxygen coverage without qualifying test results
- Commercial payers vary widely in coverage for ILD-specific pulmonary rehabilitation — verify individual LCD/NCD applicability before billing
What Coding Errors Should You Avoid With J84.89?
The J84 subcategory contains one of the more complex exclusion note structures in the respiratory chapter. Errors here tend to generate both claim denials and downstream audit exposure.
- Defaulting to J84.89 before checking for a more specific code — this is the most frequent error; always evaluate J84.112, J84.113, J84.116 before settling on J84.89
- Using J84.89 for drug-induced ILD — drug-induced interstitial lung disorders belong in J70.2–J70.4; however, if documentation supports non-drug-induced ILD in a patient who also takes implicated medications, careful provider query may be warranted
- Omitting the underlying CTD code — coding J84.89 alone when the ILD is secondary to rheumatoid arthritis or lupus is incomplete and may trigger claim edits
- Sequencing the ILD before the CTD — when the encounter is principally for the underlying CTD management, sequence the CTD first
- Using J84.89 for exogenous lipoid pneumonia (aspiration of mineral oil or other exogenous lipids) — this belongs at J69.1, not J84.89 (Excludes1 note)
- Failing to add the drug code for drug-adverse-effect scenarios — T36–T50 with the appropriate fifth/sixth character “5” is mandatory per official coding instructions
What Do Auditors Look for When Reviewing Claims With J84.89?
Auditors commonly flag these patterns during ILD claims review:
- Absence of HRCT report in the medical record when J84.89 is the primary diagnosis
- Conflicting documentation — radiology report describing a UIP pattern while the physician codes NSIP
- Missing CTD code when the clinical notes reference an autoimmune etiology
- Repeated use of J84.89 across multiple encounters without documented re-evaluation or diagnostic refinement
- Outpatient “probable” ILD coding — a prohibited practice per official guidelines
How Does J84.89 Relate to Other ICD-10 Codes?
Understanding J84.89’s position within the ILD coding ecosystem prevents both under-coding and over-specification errors.
| Code | Relationship | Key Distinction |
|---|---|---|
| J84.9 | Alternative (less specific) | Completely unspecified ILD — use only when no type can be identified |
| J84.113 | Excludes1 (mutually exclusive) | Idiopathic NSIP specifically — cannot be coded with J84.89 |
| J84.116 | Excludes1 (mutually exclusive) | Cryptogenic organizing pneumonia — cannot be coded with J84.89 |
| J84.112 | Excludes1 via parent | Idiopathic pulmonary fibrosis — distinct entity with UIP pattern |
| J84.2 | Excludes1 (mutually exclusive) | Lymphoid interstitial pneumonia — its own code |
| J69.1 | Excludes1 (mutually exclusive) | Exogenous/aspiration lipoid pneumonia |
| J70.2–J70.4 | Related but distinct | Drug-induced ILD disorders — use instead of J84.89 for drug etiology |
| M05.xx / M32.xx | Underlying etiology | RA/SLE codes — sequence before J84.89 when ILD is a manifestation |
| I27.2x | Additional code | Pulmonary hypertension complicating ILD — code additionally when documented |
What Is the Correct Code Sequencing When J84.89 Appears With Other Diagnoses?
- CTD-associated ILD encounters: Sequence the connective tissue disease code (e.g., M05.79 for RA, M32.13 for lupus pulmonitis) first; J84.89 as an additional code when the CTD is the reason for encounter.
- ILD-focused encounters (e.g., pulmonary function testing, HRCT follow-up): J84.89 may be appropriate as the principal/first-listed code if the ILD is the primary focus of the visit.
- Drug-associated organizing pneumonia: J84.89 first, followed by the appropriate T36–T50 adverse effect code (fifth/sixth character “5”) to identify the drug.
- ILD with complicating pulmonary hypertension: J84.89 followed by I27.29 or the appropriate pulmonary hypertension code when both are documented and managed.
- Inpatient admissions: Sequence per the Uniform Hospital Discharge Data Set (UHDDS) definition — the condition chiefly responsible for the admission after study.
Real-World Coding Scenario — How J84.89 Is Applied in Practice
Patient encounter: A 58-year-old woman with a 4-year history of seropositive rheumatoid arthritis presents to a pulmonologist for progressive exertional dyspnea and dry cough. HRCT chest demonstrates bilateral ground-glass opacities and mild reticulation in a predominantly peripheral and basal pattern consistent with non-specific interstitial pneumonia (NSIP) pattern. Serologic workup is positive for RF and anti-CCP. The pulmonologist documents: “Interstitial lung disease secondary to rheumatoid arthritis, NSIP pattern on imaging. No evidence of idiopathic disease.”
Correct Code Application
- M05.79 — Seropositive rheumatoid arthritis with rheumatoid factor, multiple sites (sequenced first — underlying CTD driving the encounter)
- J84.89 — Other specified interstitial pulmonary diseases (RA-associated ILD; NSIP confirmed as non-idiopathic)
- Rationale: J84.113 is excluded because the NSIP is not idiopathic — it is attributed to RA. The ILD-specific code is J84.89, with the CTD coded first.
Common Mistake in This Scenario
- Incorrect code: J84.113 (Idiopathic non-specific interstitial pneumonitis)
- Why it fails: The Excludes1 note does not apply here, but more critically, the physician has explicitly linked the NSIP to RA — making it non-idiopathic by definition. Assigning J84.113 misrepresents the clinical picture and contradicts the physician’s documentation. Auditors reviewing this claim would flag the disconnect between the CTD in the notes and an idiopathic code on the claim.
Frequently Asked Questions About ICD-10 Code J84.89
Is ICD-10 Code J84.89 Valid for Use in 2026?
J84.89 is a valid, billable ICD-10-CM code for fiscal year 2026, effective for claims with dates of service from October 1, 2025 through September 30, 2026. The code has been active since ICD-10-CM was first implemented in FY 2016 and has not undergone description changes. Coders should verify annually against the CMS ICD-10-CM Official Guidelines release to confirm continued validity.
When Should I Use J84.89 Instead of J84.9?
J84.89 is used when the provider identifies a specific type of interstitial lung disease — such as connective tissue–associated ILD, organizing pneumonia NOS, or endogenous lipoid pneumonia — that does not have its own distinct code in the tabular. J84.9 is reserved for situations where the documentation is truly unspecified and no further clinical detail can be obtained even after provider query. Always query the provider before defaulting to J84.9 — most clinicians treating ILD patients have access to diagnostic characterization.
Can J84.89 and J84.113 Ever Be Used Together on the Same Claim?
No. J84.113 (idiopathic non-specific interstitial pneumonitis) carries an Excludes1 relationship with J84.89, meaning these two codes cannot be reported simultaneously. The distinction turns entirely on whether the NSIP is idiopathic. If the provider documents a known cause (CTD, drug), use J84.89 with additional codes as appropriate. If the NSIP is confirmed idiopathic, use J84.113 instead.
What Documentation Is Needed to Avoid a Claim Denial for J84.89?
A claim for J84.89 requires physician documentation of the specific ILD type or etiology, supporting imaging (typically HRCT with pattern description), and — when the ILD is secondary to a CTD or drug — documentation of the underlying cause with appropriate additional codes. Claims that include J84.89 without accompanying imaging reports or a clear diagnosis statement in the physician notes are high denial risks, particularly with Medicare Advantage and commercial payers.
Does J84.89 Require a Drug Code When the ILD Is Drug-Induced?
Yes. When the clinical documentation indicates that the interstitial lung disease was caused by a drug adverse effect, coders must assign an additional code from T36–T50 with the fifth or sixth character “5” to identify the specific drug. The J84.89 code alone does not capture drug causality, and omitting the drug code is considered an incomplete coding finding under OIG and payer audit standards.
What CPT Codes Are Typically Submitted With J84.89 for Outpatient Visits?
Outpatient visits for ILD management most commonly pair J84.89 with evaluation and management CPT codes (99213–99215), pulmonary function testing codes (94010, 94726, 94729), and chest CT codes (71250). When bronchoscopy is performed for diagnostic workup, CPT 31623 with BAL is frequently submitted alongside J84.89. Always confirm that the E/M documentation supports the complexity level selected.
Is J84.89 Covered by Medicare for Outpatient Pulmonology Services?
Medicare covers services billed with J84.89 when medical necessity is established through appropriate documentation. There is no national coverage determination (NCD) that specifically excludes J84.89, but local coverage determinations (LCDs) for services such as pulmonary rehabilitation, home oxygen, and antifibrotic drug authorization may impose additional documentation requirements. Coders should review applicable LCDs on the CMS Medicare Coverage Database for their MAC jurisdiction.
Key Takeaways
Applying J84.89 correctly requires active decision-making, not passive code assignment. Keep these points at the forefront:
- J84.89 is for named but uncategorized ILD types — it is not a default for unspecified ILD (that is J84.9)
- Always rule out Excludes1 codes — especially J84.113, J84.116, J69.1, and J84.2 — before assigning J84.89
- Connective tissue–associated ILD (RA-associated, lupus, Sjögren, etc.) correctly maps to J84.89 with the CTD coded first
- Drug-induced ILD belongs in J70.2–J70.4, not J84.89 — but drug-adverse-effect scenarios using J84.89 require T36–T50 additional codes
- Code sequencing is critical: when ILD is a manifestation of a CTD, sequence the CTD first in most outpatient encounters
- Omit the decimal point when submitting electronically (J8489 on claims, J84.89 in documentation)
- For ongoing compliance, reference the ICD-10-CM Official Coding Guidelines from CMS and consult AHA Coding Clinic for any emerging guidance on ILD coding scenarios
For a broader review of interstitial lung disease documentation strategies, see our related guides on medical billing documentation requirements and coding audit preparation for respiratory diagnoses.
Sources referenced in this article: CMS ICD-10-CM Official Guidelines (FY 2026); WHO ICD-10 Classification of Diseases, Respiratory Chapter; AHA Coding Clinic guidance on respiratory disease sequencing; CMS Medicare Coverage Database for LCD review.
